Payment overview · 2025
General Payments
$620.79
36 reported records · 10 companies
Healthcare provider profile · identity verified
Sameh Ibrahim Youssef, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · CORTLAND, OH · NPI 1023042850
Verified facts
What the public records show
CMS Open Payments records show Sameh Ibrahim Youssef, M.D. received $620.79 in general payments during 2025 across 36 reported records.
AstraZeneca Pharmaceuticals LP accounted for 35.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Rexulti, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Trelegy Ellipta by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Rexulti by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $219.25 | 35.3% | 8 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $149.01 | 24.0% | 15 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $66.57 | 10.7% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $46.05 | 7.4% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $43.24 | 7.0% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $24.06 | 3.9% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $23.99 | 3.9% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $17.60 | 2.8% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $15.53 | 2.5% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.49 | 2.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $620.79 | 36 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $191.03 | 6 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $149.01 | 15 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $112.62 | 5 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $108.02 | 10 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $105.65 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $27.70 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $24.06 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $23.99 | 1 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $17.60 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $15.54 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $15.54 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $15.53 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $15.53 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $15.49 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $13.54 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 81 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 87 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
87 | 28 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
62 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
81 | 21 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
47 | 14 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
87 | 24 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1740 | 485 |
| Amlodipine Besylate | Amlodipine Besylate | 1574 | 418 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1140 | 271 |
| Pantoprazole Sodium | Pantoprazole Sodium | 937 | 279 |
| Metoprolol Succinate | Metoprolol Succinate | 891 | 263 |
| Lisinopril | Lisinopril | 809 | 208 |
| Eliquis | Apixaban | 788 | 157 |
| Potassium Chloride | Potassium Chloride | 727 | 182 |
| Losartan Potassium | Losartan Potassium | 679 | 189 |
| Metoprolol Tartrate | Metoprolol Tartrate | 625 | 166 |
| Furosemide | Furosemide | 605 | 177 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 574 | 154 |
| Metformin Hcl | Metformin Hcl | 567 | 161 |
| Gabapentin | Gabapentin | 524 | 131 |
| Pravastatin Sodium | Pravastatin Sodium | 514 | 144 |
| Hydrochlorothiazide | Hydrochlorothiazide | 508 | 131 |
| Sertraline Hcl | Sertraline Hcl | 368 | 93 |
| Mirtazapine | Mirtazapine | 355 | 78 |
| Tamsulosin Hcl | Tamsulosin Hcl | 349 | 107 |
| Glipizide Er | Glipizide | 346 | 95 |
| Donepezil Hcl | Donepezil Hcl | 342 | 71 |
| Clopidogrel | Clopidogrel Bisulfate | 325 | 104 |
| Omeprazole | Omeprazole | 293 | 82 |
| Atenolol | Atenolol | 290 | 81 |
| Ezetimibe | Ezetimibe | 280 | 84 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 253 | 102 |
| Montelukast Sodium | Montelukast Sodium | 241 | 57 |
| Simvastatin | Simvastatin | 238 | 72 |
| Duloxetine Hcl | Duloxetine Hcl | 237 | 62 |
| Enalapril Maleate | Enalapril Maleate | 231 | 62 |
| Divalproex Sodium | Divalproex Sodium | 220 | 45 |
| Glipizide | Glipizide | 213 | 61 |
| Allopurinol | Allopurinol | 198 | 58 |
| Hydralazine Hcl | Hydralazine Hcl | 198 | 62 |
| Lorazepam | Lorazepam | 195 | 61 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 189 | 47 |
| Carvedilol | Carvedilol | 179 | 51 |
| Memantine Hcl | Memantine Hcl | 178 | 34 |
| Meloxicam | Meloxicam | 172 | 62 |
| Finasteride | Finasteride | 166 | 47 |
| Xarelto | Rivaroxaban | 152 | 25 |
| Prednisone | Prednisone | 151 | 78 |
| Alendronate Sodium | Alendronate Sodium | 149 | 47 |
| Fluticasone Propionate | Fluticasone Propionate | 147 | 86 |
| Warfarin Sodium | Warfarin Sodium | 146 | 37 |
| Spironolactone | Spironolactone | 132 | 36 |
| Buspirone Hcl | Buspirone Hcl | 129 | 36 |
| Famotidine | Famotidine | 125 | 31 |
| Citalopram Hbr | Citalopram Hydrobromide | 121 | 26 |
| Tramadol Hcl | Tramadol Hcl | 121 | 30 |
| Escitalopram Oxalate | Escitalopram Oxalate | 115 | 32 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 106 | 27 |
| Cefdinir | Cefdinir | 103 | 77 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 103 | 33 |
| Oxycodone Hcl | Oxycodone Hcl | 103 | 29 |
| Bumetanide | Bumetanide | 99 | 33 |
| Azithromycin | Azithromycin | 98 | 83 |
| Latanoprost | Latanoprost | 97 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 96 | 32 |
| Trazodone Hcl | Trazodone Hcl | 96 | 24 |
| Levetiracetam | Levetiracetam | 95 | 16 |
| Synthroid | Levothyroxine Sodium | 87 | 28 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 87 | 24 |
| Paroxetine Hcl | Paroxetine Hcl | 83 | 20 |
| Quetiapine Fumarate | Quetiapine Fumarate | 82 | 23 |
| Farxiga | Dapagliflozin Propanediol | 81 | 21 |
| Ondansetron Hcl | Ondansetron Hcl | 80 | 45 |
| Fluoxetine Hcl | Fluoxetine Hcl | 79 | 21 |
| Sucralfate | Sucralfate | 78 | 17 |
| Clonidine Hcl | Clonidine Hcl | 77 | 22 |
| Trulicity | Dulaglutide | 77 | 18 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 75 | 22 |
| Alprazolam | Alprazolam | 72 | 18 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 70 | 17 |
| Doxycycline Hyclate | Doxycycline Hyclate | 65 | 43 |
| Benazepril Hcl | Benazepril Hcl | 64 | 17 |
| Brilinta | Ticagrelor | 62 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 62 | 23 |
| Amiodarone Hcl | Amiodarone Hcl | 61 | 21 |
| Torsemide | Torsemide | 61 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 60 | 16 |
| Ozempic | Semaglutide | 60 | 15 |
| Baclofen | Baclofen | 59 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 58 | 15 |
| Entresto | Sacubitril/Valsartan | 57 | 16 |
| Pioglitazone Hcl | Pioglitazone Hcl | 57 | 17 |
| Valsartan | Valsartan | 57 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 56 | 16 |
| Enoxaparin Sodium | Enoxaparin Sodium | 55 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 55 | 20 |
| Jardiance | Empagliflozin | 55 | 19 |
| Ropinirole Hcl | Ropinirole Hcl | 55 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 54 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 54 | 18 |
| Repaglinide | Repaglinide | 54 | suppressed |
| Fenofibrate | Fenofibrate | 50 | 13 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 50 | 18 |
| Primidone | Primidone | 49 | 11 |
| Humalog Kwikpen U-100 | Insulin Lispro | 48 | 11 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 47 | suppressed |
| Jantoven | Warfarin Sodium | 47 | 11 |
| Metformin Hcl Er | Metformin Hcl | 47 | 15 |
| Symbicort | Budesonide/Formoterol Fumarate | 47 | 14 |
| Terazosin Hcl | Terazosin Hcl | 45 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 45 | 27 |
| Digoxin | Digoxin | 44 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 44 | 12 |
| Januvia | Sitagliptin Phosphate | 44 | 15 |
| Myrbetriq | Mirabegron | 44 | suppressed |
| Rivastigmine | Rivastigmine | 44 | suppressed |
| Ketoconazole | Ketoconazole | 43 | 28 |
| Zolpidem Tartrate | Zolpidem Tartrate | 42 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 41 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 41 | 13 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 40 | 18 |
| Ipratropium Bromide | Ipratropium Bromide | 40 | 21 |
| Nifedipine Er | Nifedipine | 40 | 13 |
| Glimepiride | Glimepiride | 37 | 12 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 37 | 12 |
| Meclizine Hcl | Meclizine Hcl | 36 | 17 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 35 | 14 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 35 | 15 |
| Cephalexin | Cephalexin | 34 | 30 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 34 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 33 | 11 |
| Risperidone | Risperidone | 33 | suppressed |
| Temazepam | Temazepam | 33 | suppressed |
| Celecoxib | Celecoxib | 32 | 16 |
| Lamotrigine | Lamotrigine | 32 | suppressed |
| Klor-Con M20 | Potassium Chloride | 31 | suppressed |
| Veltassa | Patiromer Calcium Sorbitex | 31 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 30 | 13 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 30 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 30 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 30 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 29 | 26 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 29 | suppressed |
| Linzess | Linaclotide | 29 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 29 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 28 | 14 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 28 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 27 | suppressed |
| Ranolazine Er | Ranolazine | 27 | suppressed |
| Clonazepam | Clonazepam | 26 | suppressed |
| Donepezil Hcl Odt | Donepezil Hcl | 26 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 26 | 16 |
| Levofloxacin | Levofloxacin | 25 | 20 |
| Metolazone | Metolazone | 25 | suppressed |
| Mounjaro | Tirzepatide | 25 | suppressed |
| Nitroglycerin | Nitroglycerin | 25 | 21 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 25 | 14 |
| Venlafaxine Hcl | Venlafaxine Hcl | 25 | suppressed |
| Verapamil Er | Verapamil Hcl | 25 | suppressed |
| Budesonide | Budesonide | 24 | suppressed |
| Diazepam | Diazepam | 24 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 24 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 24 | 12 |
| Valacyclovir | Valacyclovir Hcl | 24 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 23 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 23 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 23 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 23 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 23 | 18 |
| Klor-Con M10 | Potassium Chloride | 22 | suppressed |
| Repatha Sureclick | Evolocumab | 22 | suppressed |
| Timolol Maleate | Timolol Maleate | 22 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 21 | suppressed |
| Dilantin | Phenytoin | 21 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 21 | suppressed |
| Constulose | Lactulose | 20 | suppressed |
| Fluconazole | Fluconazole | 20 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 20 | suppressed |
| Methylprednisolone | Methylprednisolone | 20 | 20 |
| Topiramate | Topiramate | 20 | suppressed |
| Methocarbamol | Methocarbamol | 19 | 13 |
| Promethazine Hcl | Promethazine Hcl | 19 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 18 | 11 |
| Formoterol Fumarate | Formoterol Fumarate | 18 | suppressed |
| Gemfibrozil | Gemfibrozil | 18 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 18 | suppressed |
| Pregabalin | Pregabalin | 18 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 18 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 17 | suppressed |
| Bupropion Xl | Bupropion Hcl | 17 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 14 |
| Folic Acid | Folic Acid | 17 | suppressed |
| Ibuprofen | Ibuprofen | 17 | suppressed |
| Olanzapine | Olanzapine | 17 | suppressed |
| Bicalutamide | Bicalutamide | 16 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 16 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 16 | suppressed |
| Rexulti | Brexpiprazole | 16 | suppressed |
| Anastrozole | Anastrozole | 15 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 15 | suppressed |
| Cozaar | Losartan Potassium | 15 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 15 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 15 | suppressed |
| Movantik | Naloxegol Oxalate | 15 | suppressed |
| Polymyxin B Sul-Trimethoprim | Polymyxin B Sulf/Trimethoprim | 15 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 15 | suppressed |
| Vascepa | Icosapent Ethyl | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Clonidine | Clonidine | 14 | suppressed |
| Creon | Lipase/Protease/Amylase | 14 | suppressed |
| Dropsafe Pen Needle | Pen Needle, Diabetic, Safety | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 14 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 14 | suppressed |
| Nystatin | Nystatin | 14 | 13 |
| Verapamil Hcl | Verapamil Hcl | 14 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 14 | suppressed |
| Carbamazepine Er | Carbamazepine | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Nystop | Nystatin | 13 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Probenecid | Probenecid | 13 | suppressed |
| Scopolamine | Scopolamine | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Fycompa | Perampanel | 12 | suppressed |
| Haloperidol | Haloperidol | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | 11 |
| Ramelteon | Ramelteon | 12 | suppressed |
| Admelog Solostar | Insulin Lispro | 11 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 11 | suppressed |
| Clotrimazole | Clotrimazole | 11 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 11 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 11 | suppressed |
| Glyburide | Glyburide | 11 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Repatha Syringe | Evolocumab | 11 | suppressed |
| Roflumilast | Roflumilast | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
| Sotalol | Sotalol Hcl | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Techlite Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $620.79 · 36 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, BREZTRI, Cologuard Collection Kit, FARXIGA, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, INGREZZA, NUZYRA, OTEZLA, QULIPTA, REPATHA, REXULTI, SHINGRIX, TRELEGY ELLIPTA, UBRELVY | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error